News Article

As radiopharmaceuticals shift from niche innovation to a strategic pillar of oncology care, Dr Leonid Shapiro, Managing Partner, and Dr Nicolas Correa de Calixto, Engagement Manager at Candesic, explore what’s driving global investor and pharma interest in the June edition of LaingBuisson’s HealthcareMarkets.

With blockbuster deals, a 4x increase in clinical trials since 2018, and rising demand for targeted cancer therapies, this field is attracting some of the sector’s biggest players — from Eli Lilly and Company and Novartis to AstraZeneca and Sanofi. Radioligand therapies (targeted nuclear medicine) and advanced diagnostics are now at the forefront of precision oncology, backed by complex but increasingly resilient global supply chains.